Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.

Original title: “Enveda, an AI drugmaker, banks $311M in venture funding”

Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.

Original title: “Novartis bets up to $900M for radioligand therapy from China’s BoomRay”

Grants support studies into restorative sleep and disease mechanisms

Original title: “AstronauTx receives funding for Parkinson’s sleep research”

Looking for a biopharma job in Pennsylvania? Job postings in the state tripled year over year on BioSpace. These nine companies are hiring now.

Original title: “9 companies hiring in Pennsylvania now”

As pharmas reshore manufacturing, they’re squaring off with each other to find the right personnel to staff up their plants. That task is challenging given the limited talent pool, difficulty filling critical roles and, in some cases, competition from data centers.

Original title: “Pharmas face off for manufacturing talent amidst reshoring efforts”

After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia through the clinic.

Original title: “ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands”

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.

Original title: “Viking shares surge on updated obesity drug data”

Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more than 30% on Tuesday.

Original title: “Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations”

With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.

Original title: “Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030”

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Original title: “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide”